As we gain a better understanding of how targeting PRAME can enhance T cell-mediated tumor destruction, it may become a pivotal approach in treating cutaneous melanoma and possibly other cancers with high PRAME expression [97]. The gene discussed is PRAME; the disease is cutaneous melanoma.